RXRX insider buying and SEC filings, explained
Recursion Pharmaceuticals, Inc. · CIK 1601830
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Recursion Pharmaceuticals, LLC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$7.7M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 6, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 50,000 shares at about $4.84 ($242K), marked as a 10b5-1 plan trade. Holdings down 1% to 6,108,287 shares. | SEC filing Filed Oct 7, 2026, 6:08 PM ET |
| Oct 6, 2026 | Planned (10b5-1) | Robert Hershberg (Director) sold 25,000 shares at $5.00 ($125K), marked as a 10b5-1 plan trade. Holdings down 13% to 162,156 shares. | SEC filing Filed Oct 7, 2026, 6:08 PM ET |
| Sep 8, 2026 | Planned (10b5-1) | Najat Khan (CEO and Director) sold 22,408 shares at about $3.52 ($79K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,072,890 shares. | SEC filing Filed Sep 10, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 30,000 shares at $3.34 ($100K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,158,287 shares. | SEC filing Filed Sep 2, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 30,000 shares at $3.25 ($98K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,188,287 shares. | SEC filing Filed Aug 6, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 40,000 shares at about $3.96 ($158K), marked as a 10b5-1 plan trade. Holdings down 1% to 6,218,287 shares. | SEC filing Filed Jul 9, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Namandje Bumpus (Director) sold 3,963 shares at $3.18 ($13K), marked as a 10b5-1 plan trade. Holdings down 3% to 127,632 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Najat Khan (CEO and Director) sold 23,588 shares at about $3.58 ($84K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,175,796 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.62 ($145K), marked as a 10b5-1 plan trade. Holdings down 4% to 883,735 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Namandje Bumpus (Director) sold 4,386 shares at $3.54 ($16K), marked as a 10b5-1 plan trade. Holdings down 9% to 43,171 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 2, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 30,000 shares at $3.68 ($110K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,169,863 shares. | SEC filing Filed Jun 4, 2026 |
| May 22, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.08 ($123K), marked as a 10b5-1 plan trade. Holdings down 4% to 883,735 shares. | SEC filing Filed May 27, 2026 |
| May 7, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.37 ($135K), marked as a 10b5-1 plan trade. Holdings down 4% to 926,556 shares. | SEC filing Filed May 8, 2026 |
| May 5, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 30,000 shares at $3.52 ($106K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,199,863 shares. | SEC filing Filed May 7, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.61 ($144K), marked as a 10b5-1 plan trade. Holdings down 4% to 906,556 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 7, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.10 ($124K), marked as a 10b5-1 plan trade. Holdings down 4% to 906,556 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 7, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 30,000 shares at $3.10 ($93K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,229,863 shares. | SEC filing Filed Apr 8, 2026 |
| Mar 23, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.25 ($130K), marked as a 10b5-1 plan trade. Holdings down 4% to 906,556 shares. | SEC filing Filed Mar 25, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Ben R Taylor (CFO) sold 7,956 shares at $3.39 ($27K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,180,318 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 9, 2026 | Planned (10b5-1) | Najat Khan (CEO and Director) sold 28,298 shares at about $3.35 ($95K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,262,085 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 170,000 shares at $3.46 ($588K), marked as a 10b5-1 plan trade. Holdings down 3% to 6,259,863 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $3.46 ($138K), marked as a 10b5-1 plan trade. Holdings down 4% to 906,556 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Ben R Taylor (CFO) sold 13,426 shares at $3.08 ($41K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,195,349 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $4.12 ($165K), marked as a 10b5-1 plan trade. Holdings down 4% to 913,839 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 220,000 shares at $4.20 ($924K), marked as a 10b5-1 plan trade. Holdings down 3% to 6,429,863 shares. | SEC filing Filed Feb 6, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $4.47 ($179K), marked as a 10b5-1 plan trade. Holdings down 4% to 913,839 shares. | SEC filing Filed Jan 22, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Blake Borgeson (Director) sold 220,000 shares at $4.36 ($959K), marked as a 10b5-1 plan trade. Holdings down 3% to 6,649,863 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Christopher Gibson (Director) sold 40,000 shares at $4.25 ($170K), marked as a 10b5-1 plan trade. Holdings down 4% to 933,839 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 29, 2025 | Planned (10b5-1) | Ben R Taylor (CFO) sold 21,383 shares at $4.18 ($89K), marked as a 10b5-1 plan trade. Holdings down 3% to 761,550 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Najat Khan (Chief R&D Commercial Officer and Director) sold 124,403 shares at about $4.41 ($549K), marked as a 10b5-1 plan trade. Holdings down 17% to 611,135 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | Christopher Gibson (CEO and Director) sold 40,000 shares at $4.50 ($180K), marked as a 10b5-1 plan trade. Holdings down 4% to 913,839 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Christopher Gibson (CEO and Director) sold 40,000 shares at $4.63 ($185K), marked as a 10b5-1 plan trade. Holdings down 4% to 933,839 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 2, 2025 | Planned (10b5-1) | Blake Borgeson (Director) sold 220,000 shares at $4.37 ($961K), marked as a 10b5-1 plan trade. Holdings down 3% to 6,869,863 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 19, 2025 | Planned (10b5-1) | Christopher Gibson (CEO and Director) sold 40,000 shares at $4.16 ($166K), marked as a 10b5-1 plan trade. Holdings down 4% to 913,839 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Christopher Gibson (CEO and Director) sold 40,000 shares at $5.21 ($208K), marked as a 10b5-1 plan trade. Holdings down 4% to 974,229 shares. | SEC filing Filed Nov 6, 2025 |
53 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:32 PM ET 8-K | Earnings released (Item 2.02) Executive or director change (Item 5.02) Reg FD disclosure (Item 7.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow RXRX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.